Compare CubeSmart (CUBE) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Davita Inc — how do they compare? CubeSmart trades at $40.56 (market cap $9.19B), while Davita Inc trades at $232.01 (market cap $15.12B). The key difference: Davita Inc is the larger of the two by market cap, and CubeSmart pays a 5.22% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| CUBE | DVA | |
|---|---|---|
Market Cap | $9.19B | $15.12B |
Sector | Real Estate | Health |
52-Week High | $42.34 | $235.71 |
52-Week Low | $35.36 | $103.87 |
Enterprise Value | $12.69B | $27.67B |
Dividend Yield | 5.22% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
